By Scientia Professor Gregory John Dore

Journal articles

Sheridan DA; Hajarizadeh B; Fenwick FI; Matthews GV; Applegate T; Douglas M; Neely D; Askew B; Dore GJ; Lloyd AR; George J; Bassendine MF; Grebely J, 2016, 'Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection', Liver International, 36, pp. 1774 - 1782, http://dx.doi.org/10.1111/liv.13176

Asimakopoulos A; Mangia A; Dore GJ; Lloyd AR; George J; Eslam M, 2016, 'Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in europeans', Hepatology, 64, pp. 2264 - 2265, http://dx.doi.org/10.1002/hep.28626

Martinello M; Gane E; Hellard M; Sasadeusz J; Shaw D; Petoumenos K; Applegate T; Grebely J; Maire L; Marks P; Dore GJ; Matthews GV; Cooper D, 2016, 'Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study', Hepatology, 64, pp. 1911 - 1921, http://dx.doi.org/10.1002/hep.28844

Tsui JI; Mirzazadeh A; Hahn JA; Maher L; Bruneau J; Grebely J; Hellard M; Kim AY; Shoukry NH; Cox AL; Prins M; Dore GJ; Lauer G; Lloyd AR; Page K, 2016, 'The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males', Drug and Alcohol Dependence, 169, pp. 156 - 162, http://dx.doi.org/10.1016/j.drugalcdep.2016.10.024

Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ; Han A, 2016, 'Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014)', Journal of Hepatology, 65, pp. 1086 - 1093, http://dx.doi.org/10.1016/j.jhep.2016.08.010

Dore GJ; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Grebely J; Howe AYM; Gendrano IN; Chen E; Huang HC; Dutko FJ; Nickle DC; Nguyen BY; Wahl J; Barr E; Robertson MN; Platt HL, 2016, 'Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy a randomized trial', Annals of Internal Medicine, 165, pp. 625 - 634, http://dx.doi.org/10.7326/M16-0816

Rodrigo C; Eltahla AA; Bull RA; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Estes C; Razavi H; Lloyd AR; Luciani F, 2016, 'Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia', Journal of Infectious Diseases, 214, pp. 1383 - 1389, http://dx.doi.org/10.1093/infdis/jiw389

Alavi M; Law MG; Grebely J; Amin J; Hajarizadeh B; George J; Dore GJ; Han A, 2016, 'Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study', Journal of Hepatology, 65, pp. 879 - 887, http://dx.doi.org/10.1016/j.jhep.2016.06.025

Thabet K; Asimakopoulos A; Shojaei M; Romero-Gomez M; Mangia A; Irving WL; Berg T; Dore GJ; Grønbæk H; Sheridan D; Abate ML; Bugianesi E; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Spengler U; Nattermann J; Wahid A; Rojas A; White R; Douglas MW; McLeod D; Powell E; Liddle C; Van Der Poorten D; George J; Eslam M; Gallego-Duran R; Applegate T; Bassendine M; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2016, 'MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C', Nature Communications, 7, pp. 12757, http://dx.doi.org/10.1038/ncomms12757

Grebely J; Litwin A; Dore GJ, 2016, 'Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all', Journal of Viral Hepatitis, 23, pp. 664 - 666, http://dx.doi.org/10.1111/jvh.12550

Chen Yi Mei SLG; Burchell J; Skinner N; Millen R; Matthews G; Hellard M; Dore GJ; Desmond PV; Sundararajan V; Thompson AJ; Visvanathan K; Sasadeusz J, 2016, 'Toll-like receptor expression and signaling in peripheral blood mononuclear cells correlate with clinical outcomes in acute hepatitis c virus infection', Journal of Infectious Diseases, 214, pp. 739 - 747, http://dx.doi.org/10.1093/infdis/jiw235

Bradshaw D; Raghwani J; Jacka B; Sacks-Davis R; Lamoury F; Down I; Prestage G; Applegate TL; Hellard M; Sasadeusz J; Dore GJ; Pybus OG; Matthews GV; Danta M, 2016, 'Venue-based networks may underpin HCV transmissions amongst HIV-infected gay and bisexual men', PLoS ONE, 11, pp. e0162002, http://dx.doi.org/10.1371/journal.pone.0162002

Eslam M; Mangia A; Berg T; Chan HLY; Irving WL; Dore GJ; Abate ML; Bugianesi E; Adams LA; Najim MAM; Miele L; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Romero-Gomez M; Spengler U; Nattermann J; Rahme A; Sheridan D; Booth DR; McLeod D; Powell E; Liddle C; Douglas MW; van der Poorten D; George J; White R; Rojas A; Gallego-Duran R; Bassendine M; Wong VWS; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2016, 'Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes', Hepatology, 64, pp. 34 - 46, http://dx.doi.org/10.1002/hep.28475

Martin NK; Vickerman P; Dore GJ; Grebely J; Miners A; Cairns J; Foster GR; Hutchinson SJ; Goldberg DJ; Martin TCS; Ramsay M; Hickman M, 2016, 'Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation', Journal of Hepatology, 65, pp. 17 - 25, http://dx.doi.org/10.1016/j.jhep.2016.02.007

Moussalli J; Dore G; Platt H, 2016, 'COL 4-04 - C-EDGE CO-STAR: Efficacy of elbasvir and grazoprevir in persons who inject drugs receiving opioid agonist therapy', Medecine et Maladies Infectieuses, 46, pp. 9, http://dx.doi.org/10.1016/S0399-077X(16)30274-8

Lamoury FMJ; Hajarizadeh B; Keoshkerian E; Feld JJ; Amin J; Teutsch S; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Applegate TL; Grebely J; Dolan K, 2016, 'HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection', BMC Infectious Diseases, 16, pp. 241, http://dx.doi.org/10.1186/s12879-016-1567-2

Doyle JS; Grebely J; Spelman T; Alavi M; Matthews GV; Thompson AJ; Dore GJ; Hellard ME; Kaldor J; Marks P; Lloyd A; Haber P; French R; White P; Rawlinson W; Day C; Van Beek I; McCaughan G; Madden A; Dolan K; Farrell G; Crofts N; Sievert W; Baker D, 2016, 'Quality of life and social functioning during treatment of recent hepatitis C infection: A multi-centre prospective cohort', PLoS ONE, 11, pp. e0150655, http://dx.doi.org/10.1371/journal.pone.0150655

Bourgeois S; Grebely J; Dore GJ; Aspinall R; Rodriguez-Torres M; Fox R; Sulkowski M; Feld JJ; Carr V; Liu L; Ding X; McNally J; Osinusi A; Brainard DM; Subramanian M, 2016, 'SOF/VEL for 12 weeks is well tolerated and results in high SVR12 rates in people receiving opioid substitution therapy', HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 18, pp. 16 - 16

Jacka B; Applegate T; Poon AF; Raghwani J; Harrigan PR; Debeck K; Milloy MJ; Krajden M; Olmstead A; Joy JB; Marshall BDL; Hayashi K; Pybus OG; Lima VD; Magiorkinis G; Montaner J; Lamoury F; Dore GJ; Wood E; Grebely J, 2016, 'Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada', Journal of Hepatology, 64, pp. 1247 - 1255, http://dx.doi.org/10.1016/j.jhep.2016.02.031

Ogrunc M; Martinez-Zamudio RI; Sadoun PB; Dore G; Schwerer H; Pasero P; Lemaitre JM; Dejean A; Bischof O, 2016, 'USP1 Regulates Cellular Senescence by Controlling Genomic Integrity', Cell Reports, 15, pp. 1401 - 1411, http://dx.doi.org/10.1016/j.celrep.2016.04.033

Leroy V; Angus P; Bronowicki JP; Dore GJ; Hezode C; Pianko S; Pol S; Stuart K; Tse E; Mcphee F; Bhore R; Jimenez-Exposito MJ; Thompson AJ, 2016, 'Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)', Hepatology, 63, pp. 1430 - 1441, http://dx.doi.org/10.1002/hep.28473

Jacobson IM; Dore GJ; Foster GR, 2016, 'Erratum: Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial (Lancet (2014) 384 (403-13))', The Lancet, 387, pp. 1816, http://dx.doi.org/10.1016/S0140-6736(16)30324-5

Jacobson IM; Dore GJ; Foster GR, 2016, 'Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial (vol 384, pg 403, 2014)', LANCET, 387, pp. 1816 - 1816, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000375056100027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV, 2016, 'Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection', Open Forum Infectious Diseases, 3, pp. ofw105, http://dx.doi.org/10.1093/ofid/ofw105

Hezode C; Dore GJ; Pianko S; Pol S; Stuart K; Thompson A; Tse E; Bhore R; Jimenez-Exposito MJ, 2016, 'Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients With HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis', GASTROENTEROLOGY, 150, pp. S1096 - S1096, http://dx.doi.org/10.1016/S0016-5085(16)33701-5

Martinello M; Dore GJ, 2016, 'Editorial commentary: Interferon-free Hepatitis C treatment efficacy from clinical trials will translate to "Real World" outcomes', Clinical Infectious Diseases, 62, pp. 927 - 928, http://dx.doi.org/10.1093/cid/civ1227

MacParland SA; Fadel SM; Mihajlovic V; Fawaz A; Kim C; Nur-Ur Rahman AKM; Liu J; Kaul R; Kovacs C; Grebely J; Dore GJ; Wong DK; Ostrowski MA, 2016, 'HCV specific IL-21 producing T cells but not IL-17A producing T cells are associated with HCV viral control in HIV/HCV coinfection', PLoS ONE, 11, pp. e0154433, http://dx.doi.org/10.1371/journal.pone.0154433

Hajarizadeh B; Lamoury FMJ; Feld JJ; Amin J; Keoshkerian E; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Grebely J; Applegate TL, 2016, 'Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection', Virology Journal, 13, pp. 32, http://dx.doi.org/10.1186/s12985-016-0482-x

Grebely J; Dore GJ; Greenwald R; Swan T; Barua S; Taylor LE, 2016, 'Hepatitis c virus treatment and persons who inject drugs', Annals of Internal Medicine, 164, pp. 203, http://dx.doi.org/10.7326/l15-0485

Eslam M; Hashem AM; Romero-Gomez M; Berg T; Dore GJ; Mangia A; Chan HLY; Irving WL; Sheridan D; Abate ML; Adams LA; Weltman M; Bugianesi E; Spengler U; Shaker O; Fischer J; Mollison L; Cheng W; Nattermann J; Riordan S; Miele L; Kelaeng KS; Ampuero J; Ahlenstiel G; McLeod D; Powell E; Liddle C; Douglas MW; Booth DR; George J, 2016, 'FibroGENE: A gene-based model for staging liver fibrosis', Journal of Hepatology, 64, pp. 390 - 398, http://dx.doi.org/10.1016/j.jhep.2015.11.008

Grebely J; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Phung N; Weltman MD; Day CA; Treloar C; Bath N; Haber PS; Dore GJ, 2016, 'Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS Study', Addiction, 111, pp. 311 - 319, http://dx.doi.org/10.1111/add.13197

Day CA; Shanahan M; Wand H; Topp L; Haber PS; Rodgers C; Deacon R; Walsh N; Kaldor J; van Beek I; Maher L; Day C; Lloyd A; Dore GJ; Walsh N, 2016, 'Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial', Journal of Clinical Virology, 74, pp. 66 - 72, http://dx.doi.org/10.1016/j.jcv.2015.11.031

Dore GJ; Conway B; Luo Y; Janczewska E; Knysz B; Liu Y; Streinu-Cercel A; Caruntu FA; Curescu M; Skoien R; Ghesquiere W; Mazur W; Soza A; Fuster F; Greenbloom S; Motoc A; Arama V; Shaw D; Tornai I; Sasadeusz J; Dalgard O; Sullivan D; Liu X; Kapoor M; Campbell A; Podsadecki T, 2016, 'Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials', Journal of Hepatology, 64, pp. 19 - 28, http://dx.doi.org/10.1016/j.jhep.2015.08.015

Hajarizadeh B; Grebely J; Martinello M; Matthews GV; Lloyd AR; Dore GJ, 2016, 'Hepatitis C treatment as prevention: evidence, feasibility, and challenges', The Lancet Gastroenterology and Hepatology, 1, pp. 317 - 327, http://dx.doi.org/10.1016/S2468-1253(16)30075-9

Bartlett SR; Jacka B; Bull RA; Luciani F; Matthews GV; Lamoury FMJ; Hellard ME; Hajarizadeh B; Teutsch S; White B; Maher L; Dore GJ; Lloyd AR; Grebely J; Applegate TL, 2016, 'HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection', Infection, Genetics and Evolution, 37, pp. 252 - 258, http://dx.doi.org/10.1016/j.meegid.2015.11.028

Page K; Mirzazadeh A; Rice TM; Grebely J; Kim AY; Cox AL; Morris MD; Hellard M; Bruneau J; Shoukry NH; Dore GJ; Maher L; Lloyd AR; Lauer G; Prins M; McGovern BH, 2016, 'Interferon lambda 4 genotype is associated with jaundice and elevated aminotransferase levels during acute hepatitis C virus infection: Findings from the InC3 collaborative', Open Forum Infectious Diseases, 3, pp. ofw024, http://dx.doi.org/10.1093/ofid/ofw024

Martinello M; Amin J; Matthews GV; Dore GJ, 2016, 'Prevalence and disease burden of HCV coinfection in HIV cohorts in the Asia pacific region: A systematic review and meta-analysis', AIDS Reviews, 18, pp. 69 - 80

Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies', ANTIVIRAL THERAPY, 21, pp. 425 - 434, http://dx.doi.org/10.3851/imp3035

Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies', Antiviral therapy, 21, pp. 465, http://dx.doi.org/10.3851/IMP3073

Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2016, 'The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', ANTIVIRAL THERAPY, 21, pp. 127 - 132, http://dx.doi.org/10.3851/imp2984

Hezode C; Dore G; Pianko S; Pol S; Stuart K; Thompson A; Tse E; Bhore R; Jimenez-Exposito MJ, 2016, 'Daclatasvir plus Sofosbuvir plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients with HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis', Journal of Hepatology, 64, pp. S753 - S754, http://dx.doi.org/10.1016/s0168-8278(16)01469-0

Grebely J; Flamm S; Zeuzem S; Hyland R; Chang P; Ding X; Yun C; Brainard D; McHutchison J; Forns X; Mangia A; Dore G, 2016, 'On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome during Therapy with Ledipasvir-Sofosbuvi with or without Ribavirin in the Phase 3 ION-1 Study', Journal of Hepatology, 64, pp. S776 - S777, http://dx.doi.org/10.1016/s0168-8278(16)01514-2

Gastroenterology CAO; For The Study Of The Liver CA, 2016, 'Program and Abstracts from the Canadian Digestive Diseases Week™ 2016.', Can J Gastroenterol Hepatol, 2016, pp. 4792898, http://dx.doi.org/10.1155/2016/4792898

Grebely J; Dore GJ; Aspinall R; Rodriguez-Torres M; Fox R; Liu L; Ding X; McNally J; Osinusi A; Brainard D; Subramanian M; Sulkowski M; Feld J, 2016, 'SOF/VEL for 12 Weeks Is Well Tolerated and Results in High SVR12 Rates in People Receiving Opioid Substitution Therapy', Journal of Hepatology, 64, pp. S776 - S776, http://dx.doi.org/10.1016/s0168-8278(16)01513-0

Aghemo A; Dore GJ; Hatzakis A; Wedemeyer H; Razavi H, 2015, 'Estimating HCV disease burden - Volume 3 (editorial)', Journal of Viral Hepatitis, 22, pp. 1 - 3, http://dx.doi.org/10.1111/jvh.12473

Doyle JS; Deterding K; Grebely J; Wedemeyer H; Sacks-Davis R; Spelman T; Matthews G; Rice TM; Morris MD; McGovern BH; Kim AY; Bruneau J; Lloyd AR; Page K; Manns MP; Hellard ME; Dore GJ; Maher L, 2015, 'Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort', Journal of Viral Hepatitis, 22, pp. 1020 - 1032, http://dx.doi.org/10.1111/jvh.12429

Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CAM; Rajender Reddy K; Roberts SK, 2015, 'Sofosbuvir plus velpatasvir combination therapy for treatment- Experienced patients with genotype 1 or 3 hepatitis c virus infection', Annals of Internal Medicine, 163, pp. 809 - 817, http://dx.doi.org/10.7326/M15-1014

Alavi M; Micallef M; Fortier E; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Grebely J, 2015, 'Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: The ETHOS study', Journal of Viral Hepatitis, 22, pp. 914 - 925, http://dx.doi.org/10.1111/jvh.12415

Sacks-Davis R; Grebely J; Dore GJ; Osburn W; Cox AL; Rice TM; Spelman T; Bruneau J; Prins M; Kim AY; Mcgovern BH; Shoukry NH; Schinkel J; Allen TM; Morris M; Hajarizadeh B; Maher L; Lloyd AR; Page K; Hellard M; Matthews G, 2015, 'Hepatitis c virus reinfection and spontaneous clearance of reinfection - The InC³ study', Journal of Infectious Diseases, 212, pp. 1407 - 1419, http://dx.doi.org/10.1093/infdis/jiv220

Grebely J; Bruggmann P; Treloar C; Byrne J; Rhodes T; Dore GJ, 2015, 'Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs', International Journal of Drug Policy, 26, pp. 1039 - 1040, http://dx.doi.org/10.1016/j.drugpo.2015.07.008

Back to profile page